Scoop: A2 Bio­ther­a­peu­tics rais­es $62M for sol­id tu­mor cell ther­a­pies

A2 Bio­ther­a­peu­tics has se­cured $62 mil­lion in new fi­nanc­ing — and plans to send two new cell ther­a­pies in­to the clin­ic in the new year with it.

The Se­ries B ex­ten­sion will pri­mar­i­ly bankroll two planned Phase I stud­ies for A2’s can­di­dates, CEO Scott Forak­er con­firmed to End­points News via email. Forak­er de­clined to elab­o­rate on the na­ture of an ad­di­tion­al $10 mil­lion doc­u­ment­ed in an SEC fil­ing last week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER